These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21122531)

  • 1. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.
    Chowers Y; Sturm A; Sans M; Papadakis K; Gazouli M; Harbord M; Jahnel J; Mantzaris GJ; Meier J; Mottet C; Peyrin-Biroulet L; Allez M
    J Crohns Colitis; 2010 Oct; 4(4):367-76. PubMed ID: 21122531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
    Allez M; Karmiris K; Louis E; Van Assche G; Ben-Horin S; Klein A; Van der Woude J; Baert F; Eliakim R; Katsanos K; Brynskov J; Steinwurz F; Danese S; Vermeire S; Teillaud JL; Lémann M; Chowers Y
    J Crohns Colitis; 2010 Oct; 4(4):355-66. PubMed ID: 21122530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
    McRae BL; Levin AD; Wildenberg ME; Koelink PJ; Bousquet P; Mikaelian I; Sterman AS; Bryant S; D'Haens G; Kamath R; Salfeld J; van den Brink GR
    J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
    Peng JC; Shen J; Ran ZH
    J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inflammatory bowel disease: anti-TNF strategies and beyond].
    Hoffmann JC
    Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S76-8. PubMed ID: 15368175
    [No Abstract]   [Full Text] [Related]  

  • 9. Associations Between Obesity and the Effectiveness of Anti-Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis.
    Dai ZH; Xu XT; Ran ZH
    Ann Pharmacother; 2020 Aug; 54(8):729-741. PubMed ID: 31955605
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
    Drugs R D; 1999 Mar; 1(3):253-5. PubMed ID: 10566038
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential avenues for immunotherapy of colitis-associated neoplasia.
    Waldner MJ; Neurath MF
    Immunotherapy; 2012 Apr; 4(4):397-405. PubMed ID: 22512634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW; Fedorak RN
    Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
    van Deventer SJ
    Ned Tijdschr Geneeskd; 1997 Oct; 141(41):1956-9. PubMed ID: 9550744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic inflammatory bowel disease--pathogenic concepts and therapeutic perspectives].
    Madsen JR
    Ugeskr Laeger; 2000 Mar; 162(10):1361-6. PubMed ID: 10745672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.